Abstracts

Exploring Long-Term Adherence Markers Using Hair and Dried Blood Spots in iPrEX OLE

Background: Adherence to tenofovir/emtricitabine (TFV/FTC)-based PrEP is critical to efficacy. The limitations of self-reported adherence in reliably capturing TFV/FTC exposure are well-known, raising interest in pharmacologic measures where drug levels are assessed in a biomatrix (e.g. plasma, peripheral blood mononuclear cells (PBMCs), dried blood spots (DBS), hair). Plasma and PBMC collection can be challenging, require…

UGT1A1 Genotype Predicts Bilirubin-Related Discontinuation of Atazanavir/Ritonavir

Background: Atazanavir (ATV) increases direct bilirubin (bili) levels which may cause jaundice. Concern about this deters initial prescribing of ATV. AIDS Clinical Trials Group (ACTG) protocol A5257 showed inferior tolerability of ATV/ritonavir (/r) versus both darunavir (DRV)/r and raltegravir (RAL), all with tenofovir/emtricitabine, as initial HIV therapy. We characterized genetic and clinical determinants of premature…

ABCB1 Polymorphism Affects Tenofovir Exposure as Determined by Areas-Under-the-Time-Concentration-Curve With 24-hour Intensive Pharmacokinetic Monitoring

Background: Although tenofovir (TFV) is commonly used in HIV treatment and prevention, pharmacogenomic studies of this agent are limited. Modeling of genetic factors with other determinants of exposure is important. We performed intensive pharmacokinetic (iPK) studies in a diverse cohort of HIV-infected women and identified single nucleotide polymorphisms (SNPs) in genes associated with tenofovir (TFV)…

Pharmacogenomics of Plasma Tenofovir Clearance and Change in Creatinine Clearance

Background: Candidate gene studies have reported associations between single nucleotide polymorphisms (SNPs, e.g. ABCC2 -24TÇC, rs717620) and renal toxicity with tenofovir (TFV) disoproxil fumarate (TDF). We performed genome-wide association analyses of plasma TFV clearance, and change in creatinine clearance (CrCl) in AIDS Clinical Trails Group protocol A5202. Methods: In A5202, 1858 HIV-infected subjects were randomized…

Variant ITPA Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels

Background: Background: Single nucleotide polymorphisms (SNPs) in the rs1127354 and/or rs7270101 genes encoding the inosine triphosphatase (ITPA) enzyme provide protection against ribavirin (RBV)-induced hemolytic anemia. The effect of these SNPs on the active triphosphate (TP) form of RBV has not been assessed. We sought to determine if there was an association between ITPA genetics and…

EFV but Not ATV/r Significantly Reduces Atovaquone Concentrations in HIV+ Subjects

Background: Atovaquone is an alternative agent for prophylaxis and treatment of PCP and toxoplasmosis. Previous studies have shown that average steady state atovaquone concentrations (Cavg) ≥14 μg/mL and ≥18.5 μg/mL are predictive of successful treatment of PCP and toxoplasmosis, respectively. In a recent study, atovaquone exposure following a single dose of atovaquone/proguanil was reduced by…

Drug-Drug Interaction Between HCV Inhibitors Grazoprevir/Elbasvir With Dolutegravir

Background: Grazoprevir (MK-5172) is a potent, once-daily inhibitor of the hepatitis C virus (HCV) NS3/4A protease and elbasvir (MK-8742) is a potent, once-daily HCV NS5A replication complex inhibitor that are being developed as a fixed-dose combination therapy for the treatment of chronic HCV infection in mono- and HCV/human immunodeficiency virus (HIV)-coinfected patients. This study evaluated…

HIV-1 Attachment Inhibitor Prodrug BMS-663068: Interactions with DRV/r and/or ETR

Background: BMS-663068 is a prodrug of BMS-626529, a first-in-class attachment inhibitor that binds directly to HIV-1 gp120, preventing initial viral attachment and entry into host CD4+ T-cells. Phase 2b data (through Week 24) show BMS-663068 has similar efficacy to ATV/r (both combined with RAL+TDF) in treatment-experienced (TE), HIV-1-infected subjects (sbj). Darunavir/ritonavir (DRV/r) and etravirine (ETR)…